Karius delivers genomic insights into infectious diseases, helping clinicians make critical, life-saving treatment decisions.
Karius has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
Karius's investors include General Catalyst, Lightspeed Venture Partners, Khosla Ventures, Tencent, DCVC.
Karius is headquartered in Redwood City, United States.
Karius delivers genomic insights into infectious diseases, helping clinicians make critical, life-saving treatment decisions.
Karius is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Karius — Funding & Investors." VCBacked, May 2, 2024, https://www.vcbacked.co/company/karius. Accessed September 14, 2026.
VCBacked. (2024). Karius — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/karius
{{cite web |title=Karius — Funding & Investors |url=https://www.vcbacked.co/company/karius |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated